Search Result

Pathways Recommended:	Immunology/Inflammation

Results for "

inflammation sepsis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (3) Amyloid-β (1) Apoptosis (4) Aquaporin (1) Bacterial (1) Caspase (1) CD47 (1) CXCR (2) DNA/RNA Synthesis (3) Endogenous Metabolite (1) Ferroptosis (1) HSV (1) IKK (1) mAChR (1) Macrophage migration inhibitory factor (MIF) (1) MAPKAPK2 (MK2) (2) MARK (1) Mixed Lineage Kinase (1) MMP (3) NF-κB (2) NO Synthase (2) NOD-like Receptor (NLR) (1) p38 MAPK (3) PI3K (3) Potassium Channel (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (1) Reference Standards (1) RIP kinase (2) ROS Kinase (2) Ser/Thr Protease (1) Toll-like Receptor (TLR) (2) Virus Protease (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Infection (4) Inflammation/Immunology (20) Metabolic Disease (6) Neurological Disease (6)

By Targets:

Adrenergic Receptor (1)

Akt (3)

Amyloid-β (1)

Apoptosis (4)

Aquaporin (1)

Bacterial (1)

Caspase (1)

CD47 (1)

CXCR (2)

DNA/RNA Synthesis (3)

Endogenous Metabolite (1)

Ferroptosis (1)

HSV (1)

IKK (1)

mAChR (1)

Macrophage migration inhibitory factor (MIF) (1)

MAPKAPK2 (MK2) (2)

MARK (1)

Mixed Lineage Kinase (1)

MMP (3)

NF-κB (2)

NO Synthase (2)

NOD-like Receptor (NLR) (1)

p38 MAPK (3)

PI3K (3)

Potassium Channel (1)

Pyroptosis (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

RIP kinase (2)

ROS Kinase (2)

Ser/Thr Protease (1)

Toll-like Receptor (TLR) (2)

Virus Protease (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (2)

Infection (4)

Inflammation/Immunology (20)

Metabolic Disease (6)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3612

CTCE-0214	CXCR	Inflammation/Immunology
CTCE-0214 is a chemokine CXC receptor 4 (CXCR4) agonist, SDF-1α (stromal cell-derived factor-1α) peptide analog. CTCE-0214 shows anti-inflammatory activity, and can be used in inflammation sepsis and systemic inflammatory syndromes research .

HY-W011641

(±)-Naringenin 4 Publications Verification	Potassium Channel Toll-like Receptor (TLR) NF-κB Apoptosis Caspase	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
(±)-Naringenin is an orally available anti-inflammatory agent that can regulate both acute and chronic inflammation responses, while also showing antioxidant, neuroprotective, liver-protective, and anti-cancer effects. (±)-Naringenin promotes vasodilation in endothelial cells by activating BK_Ca channels in muscle cells. It also exerts protective effects against experimental colitis by inhibiting Toll-like receptor 4/NF-κB signaling, making it useful in studies related to sepsis, fulminant hepatitis, fibrosis, and cancer research .

HY-P4846

Ac-Pro-Gly-Pro-OH	CXCR	Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and can be used as CXCR2 agonist. Ac-Pro-Gly-Pro-OH elicits bactericidal activity and inhibits lung inflammation, reducing immune cell apoptosis. Ac-Pro-Gly-Pro-OH enhances the production of type 1 cytokines (IFN-γ and IL-12) but inhibits the production of proinflammatory cytokines. Ac-Pro-Gly-Pro-OH has the potential for the research of sepsis .

HY-161834

RG100204	Pyroptosis Aquaporin NOD-like Receptor (NLR) p38 MAPK	Infection Metabolic Disease Inflammation/Immunology
RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H ²O ². RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .

HY-163694

ADRA2A antagonist 1	Adrenergic Receptor	Inflammation/Immunology
ADRA2A antagonist 1 (compd 4n) is a potent and selective ADRA2A antagonist with an IC₅₀ of 18 nM. ADRA2A antagonist 1 can be used for inflammation and sepsis research .

HY-143456

Anti-inflammatory agent 18	NO Synthase	Inflammation/Immunology
Anti-inflammatory agent 18 (compound 3b) shows NO inhibitory activity, with an IC₅₀ of 15.94 μM. Anti-inflammatory agent 18 inhibits HMGB1-induced later inflammation. Anti-inflammatory agent 18 can be used for the research of later inflammation diseases such as coronavirus diseases (COVID-19) and sepsis, etc .

HY-143457

Anti-inflammatory agent 19	NO Synthase	Inflammation/Immunology
Anti-inflammatory agent 19 (compound 2b) shows NO inhibitory activity, with an IC₅₀ of 36.00 μM. Anti-inflammatory agent 19 inhibits HMGB1-induced later inflammation. Anti-inflammatory agent 19 can be used for the research of later inflammation diseases such as coronavirus diseases (COVID-19) and sepsis, etc .

HY-161471

DCLK1-IN-5	Ser/Thr Protease	Inflammation/Immunology
DCLK1-IN-5 (Compound a24) is a DCLK1 inhibitor (IC₅₀: 179.7 nM). DCLK1-IN-5 inhibits lipopolysaccharide (HY-D1056)-induced inflammation via inhibiting DCLK1-mediated IKKβ phosphorylation. DCLK1-IN-5 protects mice against inflammation-induced lung injury and sepsis .

HY-156367

RIPK1-IN-16	RIP kinase	Inflammation/Immunology
RIPK1-IN-16 is an orally active and potent inhibitor of RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis .

HY-174842

HTS05585	Macrophage migration inhibitory factor (MIF)	Inflammation/Immunology
HTS05585 (Compound Hit-1) is a selective macrophage migration inhibitory factor (MIF) inhibitor with a K_d value of 0.29 μM measured by microscale thermophoresis (MST) and 0.32±0.01 μM verified by isothermal titration calorimetry (ITC). HTS05585 inhibits the release of pro-inflammatory factors (TNF-α, IL-6, IL-1β) from LPS-induced macrophages. HTS05585 is promising for research of inflammation-related diseases such as sepsis .

HY-14562

TBPB	mAChR Amyloid-β	Neurological Disease Inflammation/Immunology
TBPB (tert-butyl peroxybenzoate) is a highly selective, blood-brain-permeable M1 mAChR allosteric agonist (EC₅₀=289 nM) with anti-schizophrenia and anti-inflammatory activities. TBPB can enhance the sensitivity of M1 receptors to acetylcholine, activate downstream signaling pathways, and inhibit the release of pro-inflammatory cytokines (TNF-α, IL-6). TBPB can regulate the processing of amyloid and can be used in the study of neurodegenerative diseases (such as Alzheimer's disease) and inflammation-related diseases (such as sepsis) .

HY-126154

L48H37	Toll-like Receptor (TLR)	Inflammation/Immunology
L48H37 is an analog of Curcumin (HY-N0005) with improved chemical stability. L48H37 is a potent and specific myeloid differentiation protein 2 (MD2) inhibitor and inhibits the interaction and signaling transduction of LPS-TLR4/MD2. L48H37 is used for the research of sepsis or lung injury treatment .

HY-N2393

Kukoamine B	Apoptosis MMP MAPKAPK2 (MK2) p38 MAPK PI3K Akt Reactive Oxygen Species (ROS) DNA/RNA Synthesis	Neurological Disease Metabolic Disease Inflammation/Immunology
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with K_d values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis .

HY-N2393A

Kukoamine B mesylate	Apoptosis MMP MARK PI3K Akt ROS Kinase DNA/RNA Synthesis	Neurological Disease Metabolic Disease Inflammation/Immunology
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with K_d values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .

HY-N2393S

Kukoamine B-d5 dihydrochloride	MMP Apoptosis MAPKAPK2 (MK2) p38 MAPK PI3K Akt ROS Kinase DNA/RNA Synthesis	Neurological Disease Metabolic Disease Inflammation/Immunology
Kukoamine B, a spermine alkaloid, is a potent dual LPS and CpG DNA inhibitor with K_d values of 1.23 µM and 0.66 µM, respectively. Kukoamine B exerts anti-inflammatory, anti-diabetic, anti-oxidant, anti-osteoporotic and neuroprotective effects. Kukoamine B has the potential for the study of sepsis. .

HY-N2909

Aurantiamide	NF-κB RIP kinase Mixed Lineage Kinase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Aurantiamide is a non-covalent, orally active, blood-brain-permeable GRPR selective antagonist with anti-inflammatory and neuroprotective effects. Aurantiamide reduces inflammation and oxidative stress in renal tissue by inhibiting GRPR-mediated renal necrosis pathways (such as RIPK3/MLKL signaling) and NF-κB inflammatory pathways, exerting anti-acute kidney injury and endothelial function activities. Aurantiamide also inhibits the M1 polarization of microglia and inhibits NLRP3 activation, thereby improving AD mouse models. Aurantiamide has in vivo inhibitory efficacy in acute kidney injury models such as ischemia/reperfusion, sepsis, and hypertension models .

HY-P3496

Pep19-2.5	Pyroptosis	Inflammation/Immunology
Pep19-2.5 is an synthetic and antitoxin peptide, blocks the intracellular endotoxin signaling cascade. Pep19-2.5 inhibits signaling of lipopeptides (LP) and lipopolysaccharides (LPS) mediated by transmembrane and cytosolic pattern recognition receptors (PRRs). The signaling cascades lead to inflammation and cell pyroptosis .

HY-N6871

Abietic acid 1 Publications Verification	Bacterial IKK Ferroptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .

HY-N0469R

L-Lysine (Standard)	Reference Standards Endogenous Metabolite Virus Protease HSV	Infection Metabolic Disease Inflammation/Immunology
L-Lysine (Standard) is the analytical standard of L-Lysine. This product is intended for research and analytical applications. L-lysine is an essential amino acid for humans with orally activity. L-lysine can inhibit the occurrence of HSV infections and is used in herpes research. L-lysine increases calcium absorption, reduces diabetes-related diseases, improves gut health, and alleviates pancreatic inflammation. L-lysine can be used in research on metabolism, infection, and inflammation . IC₅₀ & Target:L-lysine (150 mg/kg) promotes, but not initiates, bladder cancer. The administration of L-lysine to rats submitted to colovesical cystoplasty accelerates the development of transitional metaplasia of the intestinal epithelium . L-lysine (10 mg/kg) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity . In Vivo:L-lysine (10?mg/kg, p.o., pre-treated or post-treated, administration duration 15 days) treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhance antioxidant activity in acute pancreatitis mice model . L-lysine (5 or 10?mg/kg, p.o., 45 days) ameliorates sepsis-induced acute lung injury in a lipopolysaccharide (HY-D1056)-induced mouse model .

HY-P990131

Anti-Mouse CD47/IAP Antibody (MIAP301) 1 Publications Verification	CD47	Infection Inflammation/Immunology Cancer
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for research on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .

Cat. No.	Product Name	Target	Research Area